The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study
Abstract
This study examined the incidence, clinical course and its risk factors for major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy. Ninety-nine subjects underwent the psychiatric interviews for diagnosis of major depressive episode according to the DSM-IV criteria before the start of interferon therapy, and once every 4 weeks during both the 24-week treatment period and 12 weeks after the end of therapy. Depressive symptoms were also evaluated using the Hamilton Rating Scale for Depression. Major depression occurred during interferon therapy in 23 patients (23.2%). In 73.9% of them depression occurred within 8 weeks after the start of therapy. Twenty-two patients with depression completed the therapy and 59.1% of them achieved remission by the end of therapy with a mean duration of 11.6 weeks. Although the other 40.9% were not in remission at the end of therapy, they achieved remission within 12 weeks thereafter. The only risk factor for depression was advanced age. Depression occurs frequently among patients with hepatitis type C undergoing interferon-alpha therapy. Such patients require careful observation, and psychiatrists should be sufficiently aware of this significant psychiatric complication of interferon therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Depression occurs frequently in patients with hepatitis C undergoing INF treatment.”
From Neuroinflammation and cytokine abnormality in major depression: cause or consequence in that illness? (2016) · cites this paper as [20]
In the citing paper
“Of note in one study, 23% of patients during INF treatment satisfied the diagnostic criteria for major depressive disorders; in 74% of them depression occurred within 2 mo after the start of INF treatment[20].”
From Neuroinflammation and cytokine abnormality in major depression: cause or consequence in that illness? (2016) · cites this paper as [20]
In the citing paper
“When IFN-α was used in cancer patients as an immunotherapy, the patients developed depression.”
From Neuroinflammation and cytokine abnormality in major depression: cause or consequence in that illness? (2016) · cites this paper as [20]
In the citing paper
“When the immunotherapy was discontinued or antidepressants were administered, the depressive symptoms improved[20,21].”
From Neuroinflammation and cytokine abnormality in major depression: cause or consequence in that illness? (2016) · cites this paper as [20]
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
A self-rating depression scale
ZUNG, W. W. K. (1965) · Archives of General Psychiatry · doi:10.1001/archpsyc.1965.01720310065008 · Cited by 9,813
A personality scale of manifest anxiety
Taylor, J. A. (1953) · The Journal of Abnormal and Social Psychology · doi:10.1037/h0056264 · Cited by 3,131
Winearls, C., Pippard, M. J., Downing, M. R., Oliver, D., Reid, C. D. L., & Cotes, P. M. (1986) · The Lancet · doi:10.1016/s0140-6736(86)92192-6 · Cited by 1,401
Paroxetine for the prevention of depression induced by high-dose interferon alfa.
Musselman, D. L., Lawson, D. H., Gumnick, J. F., Manatunga, A. K., Penna, S., Goodkin, R. S., Greiner, K., Nemeroff, C. B., & Miller, A. H. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103293441303 · Cited by 1,120
Conry‐Cantilena, C., VanRaden, M. J., Gibble, J. W., Melpolder, J. C., Shakil, A. O., Viladomiu, L., Cheung, L., DIBISCEGLIE, A., Hoofnagle, J. H., Shih, J. W., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199606273342602 · Cited by 627
Neuropsychiatric Symptoms Associated With Hepatitis C and Interferon Alpha: A Review
Dieperink, E. W., Willenbring, M., & Ho, S. B. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.6.867 · Cited by 417
Psychiatric Complications of Long-term Interferon Alfa Therapy
Renault, P. F. (1987) · Archives of Internal Medicine · doi:10.1001/archinte.1987.00370090055011 · Cited by 413
Side effects of α interferon in chronic hepatitis C
Dusheiko, G. M. (1997) · Hepatology · doi:10.1002/hep.510260720 · Cited by 394
Depression, fatigue, and functional disability in patients with chronic hepatitis C
Dwight, M. M., Kowdley, K. V., Russo, J. E., Ciechanowski, P. S., Larson, A. M., & Katon, W. J. (2000) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(00)00155-0 · Cited by 258
INTERFERONS AS MEDIATORS OF PSYCHIATRIC MORBIDITY
Mcdonald, E. M., Mann, A. H., & Thomas, H. C. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91319-5 · Cited by 248
Suicide associated with alfa-interferon therapy for chronic viral hepatitis
Janssen, H. L. A., Brouwer, J. T., van der Mast, R. C., & Schalm, S. W. (1994) · Journal of Hepatology · doi:10.1016/s0168-8278(05)80402-7 · Cited by 229
Capuron, L., & Ravaud, A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401716 · Cited by 169
Treatment with interferon-α in patients with chronic hepatitis and mood or anxiety disorders
Pariante, C. M., Orrù, M. G., Baita, A., Farci, M. G., & Carpiniello, B. (1999) · The Lancet · doi:10.1016/s0140-6736(98)04793-x · Cited by 164
Effect of Interferon-α Treatment of Chronic Hepatitis C on Health-Related Quality of Life
Hunt, C. M., Dominitz, J. A., Phillips‐Bute, B. G., Waters, B., Blasi, U., & Williams, D. M. (1997) · Digestive Diseases and Sciences · doi:10.1023/a:1018852309885 · Cited by 141
Depression From Interferon Therapy in Patients With Hepatitis C
Miyaoka, H., Otsubo, T., Kamijima, K., Ishii, M., ONUKI, M., & Mitamura, K. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.7.1120 · Cited by 135
Fluoxetine treatment of depression caused by interferon-alpha.
Levenson, J. L., & Fallon, H. J. (1993) · PubMed · Cited by 123
Hepatitis C Virus and Depression in Drug Users
Johnson, M. E., Fisher, D. G., Fenaughty, A. M., & Theno, S. A. (1998) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1998.225_a.x · Cited by 122
Long-term prognosis of depression in primary care.
Simon, G. E. (2000) · Europe PMC (PubMed Central) · Cited by 105
Sertraline treatment of interferon‐alfa‐induced depressive disorder
Schramm, T. M., Lawford, B. R., Cooksley, W. G. E., & Macdonald, G. A. (2000) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2000.tb125687.x · Cited by 104
Thiel, D. H. V., Friedlander, L., Molloy, P. J., FAGIUOLI, S., Kania, R. J., & Caraceni, P. (1995) · PubMed · Cited by 101
Malaguarnera, M., Fazio, I. D., Restuccia, S., Pistone, G., Ferlito, L., & Rampello, L. (1998) · Neuropsychobiology · doi:10.1159/000026485 · Cited by 95
Five Cases of Interferon-Alpha–Induced Depression Treated With Antidepressant Therapy
Gleason, O. C., & Yates, W. R. (1999) · Psychosomatics · doi:10.1016/s0033-3182(99)71190-4 · Cited by 80
Drug-Induced Cognitive Impairment
Bowen, J. D., & Larson, E. B. (1993) · Drugs & Aging · doi:10.2165/00002512-199303040-00005 · Cited by 73
Course of Depression During the Initiation of Interferon Beta-1a Treatment for Multiple Sclerosis
Mohr, D. C., Likosky, W., Dwyer, P., Wende, J. V. D., Boudewyn, A. C., & Goodkin, D. (1999) · Archives of Neurology · doi:10.1001/archneur.56.10.1263 · Cited by 68
Adams, F., Fernandez, F., & Mavligit, G. M. (1988) · Journal of Neuro-Oncology · doi:10.1007/bf00177432 · Cited by 64
Emotional state of patients with relapsing-remitting MS treated with interferon beta-1b
Borrás, C., Río, J., Porcel, J., Barrios, M., Tintoré, M., & Montalbán, X. (1999) · Neurology · doi:10.1212/wnl.52.8.1636 · Cited by 62
Behavioral assessment of patients treated with alpha‐interferon
Niiranen, A., Laaksonen, R. K., Livanainen, M., Mattson, K. V., Färkkilä, M. A., & Cantell, K. (1988) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1988.tb06395.x · Cited by 61
Noguchi, S., Sata, M., Suzuki, H., Mizokami, M., & Tanikawa, K. (1997) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365549709008659 · Cited by 60
Successful Treatment of Interferon Alfa-Induced Mood Disorder With Nortriptyline
Goldman, L. S. (1994) · Psychosomatics · doi:10.1016/s0033-3182(94)71769-2 · Cited by 59
Mulder, R., Ang, M., CHAPMAN, B. A., Ross, A., Stevens, I., & Edgar, C. L. (2000) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2000.02090.x · Cited by 58
Antidepressant Action of Sulpiride. Results of a Placebo-Controlled Double-Blind Trial
Rüther, E., Degner, D., Munzel, U., Brunner, E., Lenhard, G., Biehl, J., & Vögtle-Junkert, U. (1999) · Pharmacopsychiatry · doi:10.1055/s-2007-979218 · Cited by 53
Merimsky, O., & Chaitchik, S. (1992) · Anti-Cancer Drugs · doi:10.1097/00001813-199212000-00002 · Cited by 52
The efficacy of drug treatments for dysthymia: a systematic review and meta-analysis
de Lima, M. S., HOTOPH, M., & Wessely, S. C. (1999) · Psychological Medicine · doi:10.1017/s0033291799001324 · Cited by 48
Csako, G., McGriff, N. J., Rotman-Pikielny, P., Sarlis, N. J., & Pucino, F. (2001) · Annals of Pharmacotherapy · doi:10.1345/aph.1a031 · Cited by 40
Burns in a suicide attempt related to psychiatric side effects of interferon
Fukunishi, K., Tanaka, H., Maruyama, J., Takahashi, H., Kitagishi, H., Ueshima, T., Maruyama, K., & Sakata, I. (1998) · Burns · doi:10.1016/s0305-4179(98)00073-4 · Cited by 37
Horikawa, N., Yamazaki, T., Sagawa, M., & Nagata, T. (1999) · General Hospital Psychiatry · doi:10.1016/s0163-8343(98)00082-6 · Cited by 14
Self-citationTsukamoto, T., Asakura, M., Tsuneizumi, T., Yuko, S., Takahiro, S., & Hasegawa, K. (1994) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(94)90017-5 · Cited by 13
A Double-Blind Comparison of Sulpiride with Chlordiazepoxide in Neurosis
Toru, M., Moriya, H., Yamamoto, K., Shimazono, Y., Ishiguro, T., Sugano, K., Isse, K., & Miyasaka, M. (1976) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.1976.tb00118.x · Cited by 13
Interferon ß and suicide in multiple sclerosis
O'Connor, N. T. J. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91064-8 · Cited by 8
Caraceni (1998) · doi:10.1002/(sici)1097-0142(19980801)83:3
Research works printed but not linked: 2
- Malek-Ahmadi, 2001, Mood disorders associated with interferon treatment, Ann Pharmacother, 35, 489, 10.1345/aph.10172 · DOI · Paper page
- Horikawa, 1999, A case of akathisia during interferon-alpha therapy for chronic hepatitis type C, Gen Hosp Psychiatry, 21, 134
Cited by
Sorted by citations
Neuropsychiatric Adverse Effects of Interferon-??: Recognition and Management
Raison, C. L., Demetrashvili, M., Capuron, L., & Miller, A. H. (2005) · CNS Drugs · doi:10.2165/00023210-200519020-00002 · Cited by 483
Depression During Pegylated Interferon-Alpha Plus Ribavirin Therapy
Raison, C. L., Borisov, A. S., Broadwell, S. D., Capuron, L., Woolwine, B. J., Jacobson, I. M., Nemeroff, C. B., & Miller, A. H. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0106 · Cited by 300
Interferon-Induced Depression in Chronic Hepatitis C: A Systematic Review and Meta-Analysis
Udina, M., Castellví, P., Moreno-España, J., Navinés, R., Valdés, M., Forns, X., Langohr, K., Solà, R., Vieta, E., & Martín-Santos, R. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12r07694 · Cited by 297
Jeon, S. W., & Kim, Y. K. (2016) · World Journal of Psychiatry · doi:10.5498/wjp.v6.i3.283 · Cited by 247
Hepatitis C infection, antiviral treatment and mental health: A European expert consensus statement
Schaefer, M., Capuron, L., Friebe, A., Diez-Quevedo, C., Robaeys, G., Neri, S., Foster, G. R., Kautz, A., Forton, D., & Pariante, C. M. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.07.037 · Cited by 225
Metadata
- Authors
- Horikawa, N., Yamazaki, T., Izumi, N., & Uchihara, M.
- Affiliations
- Tokyo Women's Medical University (JP)
- Musashino Red Cross Hospital (JP)
- Corresponding author
- Horikawa, Naoshi
- ORCID
- Izumi, Namiki
- Venue
- General Hospital Psychiatry
- Publisher
- Elsevier BV
- Published
- 2003-01
- Volume
- 25
- Issue
- 1
- Pages
- 34-38
- ISSN
- 0163-8343 (ISSN-L)
- OpenAlex
- W2130844638
- Cited by
- 140
- References
- 42
- Citations by year
- 2026: 1 · 2024: 1 · 2023: 4 · 2021: 2 · 2020: 1 · 2019: 4 · 2018: 1 · 2017: 7 · 2016: 6 · 2015: 5 · 2014: 5 · 2013: 6 · 2012: 14
- FWCI
- 7.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- General Hospital Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatitis C virus research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- major depressive disorder, chronic hepatitis C, interferon-alpha therapy, antidepressant side effects, depression incidence, clinical course, remission, risk factors, old age
- MeSH terms
- Antiviral Agents, Depressive Disorder, Major, Major Depressive Disorder, Female, Humans, Male, Middle Aged, Prospective Studies, Incidence, Interferon-alpha, Hepatitis C, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
